Hepatocellular carcinoma tumor thrombus entering the inferior vena cava treated with percutaneous RF ablation: a case report.
Hepatocellular carcinoma
Locoregional therapy
Sorafenib
Tumor thrombus
US-guided radiofrequency ablation
Journal
Journal of ultrasound
ISSN: 1876-7931
Titre abrégé: J Ultrasound
Pays: Italy
ID NLM: 101315005
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
30
10
2018
accepted:
23
01
2019
pubmed:
14
3
2019
medline:
7
3
2020
entrez:
14
3
2019
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. In advanced cancer stages (metastatic disease and/or vascular invasion), the generally accepted standard of care is systemic therapy using sorafenib as first-line treatment and, recently, regorafenib and nivolumab as second-line treatment, but the quality of life and the prognosis of patients remain very poor. Our paper reports a case of US-guided radiofrequency ablation (RFA) of both intraparenchymal HCC and inferior vena cava tumor thrombus. We treated a patient with HCC associated with tumor thrombus extending into vena cava after failure of sorafenib therapy using US-guided radiofrequency ablation (RFA). A good radiological and clinical response was observed in association with excellent tolerability. The patient has been followed up for 15 months from the ablation, is alive, and is in a good clinical condition without evidence of tumor recurrence. This is the first case in which this minimally invasive percutaneous procedure has been successfully used to treat an HCC thrombus entering the vena cava.
Identifiants
pubmed: 30864004
doi: 10.1007/s40477-019-00361-w
pii: 10.1007/s40477-019-00361-w
pmc: PMC6704268
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
363-370Références
Anticancer Res. 2004 Jul-Aug;24(4):2419-21
pubmed: 15330193
World J Gastroenterol. 2005 Apr 21;11(15):2357-9
pubmed: 15818754
J Gastrointest Surg. 2006 Jun;10(6):855-62
pubmed: 16769542
Dig Dis Sci. 2007 Jun;52(6):1554-7
pubmed: 17357843
J BUON. 2007 Oct-Dec;12(4):556
pubmed: 18067220
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
AJR Am J Roentgenol. 2009 Oct;193(4):948-54
pubmed: 19770315
Am Surg. 2009 Nov;75(11):1104-8
pubmed: 19927515
AJR Am J Roentgenol. 2010 Feb;194(2):W221-6
pubmed: 20093578
Surg Today. 2011 Aug;41(8):1122-9
pubmed: 21773904
Eur J Cancer. 2012 Jul;48(10):1452-65
pubmed: 22240282
Ann Surg Oncol. 2013 Mar;20(3):914-22
pubmed: 22956071
J Gastroenterol. 2015 Apr;50(4):445-54
pubmed: 25027973
Anticancer Res. 2014 Nov;34(11):6785-90
pubmed: 25368292
Trials. 2014 Dec 03;15:474
pubmed: 25472660
J Vasc Interv Radiol. 2015 Mar;26(3):320-9.e6
pubmed: 25612807
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Liver Cancer. 2014 Oct;3(3-4):458-68
pubmed: 26280007
Medicine (Baltimore). 2015 Aug;94(34):e1049
pubmed: 26313767
World J Hepatol. 2016 Jun 18;8(17):703-15
pubmed: 27330679
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
BMC Surg. 2017 Feb 28;17(1):21
pubmed: 28245832
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
J Gastrointest Oncol. 2017 Apr;8(2):215-228
pubmed: 28480062
HPB (Oxford). 2017 Aug;19(8):659-666
pubmed: 28552299
Hepatol Int. 2017 Jul;11(4):317-370
pubmed: 28620797
World J Hepatol. 2017 Jul 28;9(21):907-920
pubmed: 28824742
J Clin Oncol. 2018 Jul 1;36(19):1913-1921
pubmed: 29498924
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281